Navigation Links
DecisionQ Partners With Thomas Jefferson University to Reveal Insights for Cancer Therapy
Date:4/29/2009

Partnership integral piece of consortium recently awarded five-year, $6.7 million Susan G. Komen for the Cure Promise Grant

WASHINGTON, April 29 /PRNewswire/ -- Thomas Jefferson University's Kimmel Cancer Center has partnered with DecisionQ, a leader in predictive analytics and machine learning to uncover life-saving answers hidden in the center's proprietary and extensive cancer registries. DecisionQ will leverage its expertise in developing predictive algorithms to identify how patients will respond to different therapeutic options for breast and colon cancers.

The team is part of a consortium that was recently awarded a Susan G. Komen for the Cure Promise Grant of nearly $6.7 million for five years of continued breast cancer research. Promise grants support multi-disciplinary research with the greatest potential to significantly reduce breast cancer incidence and/or mortality within the next decade.

"Identification of therapy-relevant biomarkers is a crucial part of breast cancer research, as there are many different biomarkers that could predict treatment response and outcome, and serve as targets for treatment," said Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at Thomas Jefferson University. "DecisionQ's Faster AnalyticsTM will be used to further refine the team's predictive models in breast cancer, helping us to identify protein biomarker patterns that can be used to make sure patients are offered the most appropriate therapy."

Leading experts in the fields of decision analysis, statistics and machine learning have developed the technology and approach that DecisionQ applies in creating MMIA's (multi marker interpretive assays), greatly enhancing the quality of human judgment in an interactive, real-time environment at a low marginal cost.

"More than a million new cancer diagnoses are documented each year, giving researchers vast amounts of data with which to work," said Todd Radano, co-founder of DecisionQ. "Applying advances in analytics via machine learning will assist scientists in taking what is known about the disease and developing actionable insights that could ultimately save lives."

About DecisionQ Corporation

DecisionQ is a leader in predictive analytics and machine learning technologies with expertise in the healthcare, life sciences, financial services and security industries. Through the application of its advanced technologies and methods it delivers customers substantial improvements in the speed and quality of decision making by allowing them to quickly turn data into actionable insights. To learn more about DecisionQ visit www.decisionq.com.

                                         Contact:
                                         Laura Phillips, Vehr Communications
                                         513.381.8347
                                         lphillips@vehrcommunications.com


'/>"/>
SOURCE DecisionQ Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. E&K Scientific Announces Partnership with Sciformatix
2. PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference
3. Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting
4. Brazils top automakers to distribute 2 million copies of the Ethanol Handbook in partnership with the Brazilian Sugarcane Industry Association
5. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
6. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG
7. US Oncology Clinical Development Attends Partnerships With CROs
8. Aviation partners to cut 500,000 tonnes of CO2 a year
9. ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions
10. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
11. Van Andel Institute Joins the MetaMiner Oncology Partnership Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):